Vertex Pharmaceuticals Incorporated has announced its intention to acquire Alpine Immune Sciences, Inc. in an all-cash transaction valued at approximately $4.9 billion, or $65 per share. The acquisition, unanimously approved by the Boards of Directors of both companies, is expected to close in Q2 of 2024, subject to majority tender and customary closing conditions. This strategic move aims to enhance Vertex's capabilities in developing transformative medicines for serious diseases with high unmet need, particularly in specialty markets. Alpine's lead asset, povetacicept, is a Phase 3-ready therapy with potential to treat IgAN, a serious autoimmune kidney disease, and other conditions. The transaction is consistent with Vertex's investment strategy and is fully funded from cash on hand. The Tender Offer Statement and related materials will be filed with the SEC at the commencement of the tender offer, and Alpine's stockholders are urged to read these materials carefully when they become available.

Vertex Pharmaceuticals Incorporated has announced its intention to acquire Alpine Immune Sciences, Inc. in an all-cash transaction valued at approximately $4.9 billion, or $65 per share. The acquisition, unanimously approved by the Boards of Directors of both companies, is expected to close in Q2 of 2024, subject to majority tender and customary closing conditions. This strategic move aims to enhance Vertex's capabilities in developing transformative medicines for serious diseases with high unmet need, particularly in specialty markets. Alpine's lead asset, povetacicept, is a Phase 3-ready therapy with potential to treat IgAN, a serious autoimmune kidney disease, and other conditions. The transaction is consistent with Vertex's investment strategy and is fully funded from cash on hand. The Tender Offer Statement and related materials will be filed with the SEC at the commencement of the tender offer, and Alpine's stockholders are urged to read these materials carefully when they become available.